Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre

被引：0
|
作者：
Chiara Catania
Gilda Ascione
Laura Adamoli
Tommaso De Pas
Marta Medici
Lucia Franceschelli
Elena Verri
Elena Magni
Giuseppina Sanna
Rosalba Torrisi
Aron Goldhirsch
Franco Nolè
机构：
[1] European Institute of Oncology,Unit for Medical Care, Division of Medical Oncology
[2] European Institute of Oncology,New Drugs Development Division
[3] European Institute of Oncology,Research Unit of Medical Senology
[4] European Institute of Oncology,Department of Medicine
来源：
Breast Cancer Research and Treatment | 2007年 / 106卷
关键词：
Breast cancer; Endocrine treatment; Fulvestrant; Postmenopausal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 103
页数：6
相关论文
共 50 条
  • [1] Fulvestrant in heavily pre-treated patients with advanced breast cancer:: results from a single compassionate use programme centre
    Catania, Chiara
    Ascione, Gilda
    Adamoli, Laura
    De Pas, Tommaso
    Medici, Marta
    Franceschelli, Lucia
    Verri, Elena
    Magni, Elena
    Sanna, Giuseppina
    Torrisi, Rosalba
    Goldhirsch, Aron
    Nole, Franco
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (01) : 97 - 103
  • [2] Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme
    Brigitte Mlineritsch
    Oskar Psenak
    Peter Mayer
    Martin Moik
    Konrad Namberger
    Cornelia Hauser-Kronberger
    Richard Greil
    Breast Cancer Research and Treatment, 2007, 106
  • [3] Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme
    Mlineritsch, Brigitte
    Psenak, Oskar
    Mayer, Peter
    Moik, Martin
    Namberger, Konrad
    Hauser-Kronberger, Cornelia
    Greil, Richard
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (01) : 105 - 112
  • [4] Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: A single-centre experience
    Steger, GG
    Bartsch, R
    Wenzel, C
    Pluschni, U
    Hussian, D
    Sevelda, U
    Locker, GJ
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (17) : 2655 - 2661
  • [5] "Ethinylestradiol" is beneficial for postmenopausal advanced breast cancer patients heavily pre-treated with endocrine agents
    Iwase, H.
    Yamamoto, Y.
    Murakami, K-I
    Yamamoto-Ibusuki, M.
    Tomita, S.
    Omoto, Y.
    CANCER RESEARCH, 2012, 72
  • [6] Eribulin monotherapy in heavily pre-treated patients with advanced breast cancer: "Real world" experience
    Sanganalmath, P.
    Purohit, K.
    Winter, M.
    Horsman, J.
    Ramakrishnan, S.
    Hatton, M.
    Lee, C.
    Dunn, K.
    Din, O.
    Coleman, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S181 - S182
  • [7] Daratumumab in heavily pre-treated patients: a single centre experience from the East of England.
    Sparksman, D.
    Cunningham, J.
    Bowles, K.
    Gomez, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 178 - 178
  • [8] Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer
    Larsen, Finn Ole
    Boisen, Mogens Karsbol
    Fromm, Annelene L.
    Jensen, Benny Vittrup
    ACTA ONCOLOGICA, 2012, 51 (02) : 231 - 233
  • [9] Treosulfan for advanced breast cancer in a heavily pre-treated patient - a case report
    Terjung, A.
    Altgassen, C.
    Friedrich, M.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2017, 38 (01) : 115 - 117
  • [10] Fulvestrant in heavily pretreated patients with advanced breast cancer:: experience from a Named Patient Programme in Switzerland
    Hawle, H.
    Thuerlimann, B.
    Pagani, O.
    Buser, K.
    Bonnefoi, H.
    Forni, M.
    Aapro, M.
    Mach, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 125 - 125
12345